GlycoEra

GlycoEra develops biologics designed to selectively target and degrade circulating extracellular proteins, such as autoantibodies, that drive autoimmune and neurological diseases. The company's lead program, GE8820, focuses on degrading pathogenic IgG4 autoantibodies without causing broad immunosuppression. Their platform aims to provide precision immunology treatments that allow for earlier disease intervention and improved patient outcomes.